Tag: US35104E1001

4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones

February 28, 2025 16:05 ET  | Source: 4D Molecular Therapeutics, Inc. Presented…

GlobeNews Wire GlobeNews Wire
undefined

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

January 29, 2025 08:00 ET  | Source: 4D Molecular Therapeutics, Inc. Initial…

GlobeNews Wire GlobeNews Wire
undefined